News | May 22, 2025
Cupid posts Q4 FY25 consolidated PAT at Rs. 11.51 Cr
The company has posted net profit of Rs. 40.88 crores for the Financial Year ended March 31, 2025
The company has posted net profit of Rs. 40.88 crores for the Financial Year ended March 31, 2025
The company has posted net profit of Rs. 1,986.43 crores for the Financial Year ended March 31, 2025
Enpatoran is a potential first-in-class oral therapy for CLE and SLE that is thought to selectively block the activation of Toll-like receptors (TLR)7 and TLR8
3SBio will receive an upfront payment of $1.25 billion and is eligible to receive milestone payments associated with certain development, regulatory and commercial milestones up to $4.8 billion
Q4 FY25 PAT stood at Rs. 90.7 crore as compared to Rs.77.6 crore in Q4 FY24
Global Health has posted net profit of Rs. 481.43 crores for the Financial Year ended March 31, 2025
EBITDA for the period rose by 23.2% to Rs. 3,797 million
Indraprastha Medical Corporation has reported total income of Rs. 340.10 crores during the period ended March 31, 2025
The company has posted net profit of Rs. 485.62 crores for the Financial Year ended March 31, 2025
The company has posted net profit of Rs. 1,414.44 crores for the Financial Year ended March 31, 2025
Subscribe To Our Newsletter & Stay Updated
